TruSight Oncology 500 clinical research solutions

Take cancer from uncertainty to insight

Enable comprehensive genomic profiling from tissue or liquid biopsies for clinical research

Three assays to fuel precision oncology research

The TruSight Oncology 500 product line offers pan-cancer next-generation sequencing assays to enable in-house comprehensive genomic profiling (CGP). Identify relevant biomarkers from key guidelines and clinical trials with one consolidated assay to get more results with less sample than iterative testing.

TruSight Oncology 500 products

TruSight Oncology 500

Enable CGP with a large pan-cancer panel covering all major variant classes plus gene signatures (TMB, MSI, and HRD) from FFPE tissue.

TruSight Oncology 500 High-Throughput

Enable CGP with a large pan-cancer panel covering all major variant classes plus gene signatures (TMB, MSI) from FFPE tissue, with added scalability.

TruSight Oncology 500 ctDNA v2

Enable CGP with a pan-cancer panel capable of detecting key IO gene signatures (TMB, MSI) plus all main variant classes from ctDNA in blood plasma.

Key features and benefits

Comprehensive

Assess > 500 pan-cancer biomarkers in a single multiplex assay, including broad genomic signatures like TMB, MSI and HRD* to increase the likelihood of identifying a relevant mutation without sequential testing.

Flexibility

Use FFPE samples or minimally invasive circulating tumor DNA (ctDNA) from liquid biopsy to complement tissue studies or if sufficient tissue is not readily available.

Reliability

Achieve consistent quality across the portfolio with robust hybrid capture chemistry, proven SBS sequencing and sophisticated bioinformatics.

In-house

Offer precision oncology in your lab to minimize sample loss, control turnaround times, monitor quality, and retain data for reanalysis as discoveries are made.

Timely

Obtain results in < 5 days with integrated library prep, sequencing, and bioinformatics options available locally or in the cloud.

Scalable

Reduce hands-on time and minimize errors with automation options. Sequence 8–192 samples per run for TruSight Oncology and TruSight Oncology High-Throughput^† and 8–48 samples per run for TruSight Oncology 500 ctDNA.

TruSight Oncology 500 portfolio
Brochure PDF 6 MB

Key biomarkers

Subset of genomic tumor profiling biomarkers for multiple cancer types^a

Pan-cancer: BRAF NTRK1 NTRK2 NTRK3 RET MSI TMB

Genes with biomarkers of significance^b							Genes with biomarkers of potential significance^c
Breast	BRCA1	BRCA2	ERBB2	ESR1	PALB2	PIK3CA	180
Colorectal	ERBB2	KRAS	NRAS				166
Bone	EGFR	ERG	ETV1	ETV4	EWSR1	FEV	140
	FLI1	FUS	H3F3A	HEY1	IGH1	MDM2
	ERBB2	NCOA2	SMARCB1
Lung	ALK	EGFR	ERBB2	KRAS	MET	NUTM1	223
Lung	ROS1						223
Melanoma	KIT	NRAS	ROS1				172
Ovarian	BRCA1	BRCA2	FOXL2				149
CNS^d	APC	ATRX	CDKN2A	CDKN2B	EGFR	H3F3A	140
	HIST1H3B	HIST1H3C	IDH1	IDH2	MYCN	PTCH1
	RELA	TERT	TP53
Prostate	AR	ATM	BARD1	BRCA1	BRCA2	BRIP1	151
	CDK12	CHEK1	CHEK2	FANCL	FGFR2	FGFR3
	PALB2	RAD51B	RAD51C	RAD51D	RAD54L
Thyroid	HRAS	KRAS	NRAS	RET	TERT		165
Uterine & cervical	BRCA2	EPC1	ERBB2	ESR1	FOXO1	GREB1	138
	JAZF1	NCOA2	NCOA3	NUTM2A	NUTM2B	PAX3
	PAX7	PHF1	POLE	SMARCA4	SUZ12	TP53
	YWHAE
Other solid tumors	ALK	APC	ARID1A	ASPSCR1	ATF1	ATIC	152
	BAP1	BCOR	BRCA1	BRCA2	CAMTA1	CARS
	CCNB2	CDK4	CDKN2A	CIC	CITED2	CLTC
	COL1A1	COL6A3	CREB1	CREB3L1	CREB3L2	CSF1
	CTNNB1	DDIT3	DDX3X	DNAJB1	DUX4	EED
	EGFR	ERBB2	ERG	ETV1	ETV4	ETV6
	EWSR1	FEV	FGFR2	FGFR3	FLI1	FOXL2
	FOXO1	FOXO4	FUS	GLI1	HEY1	HGF
	HMGA2	IDH1	KRAS	LEUTX	MAML3	MDM2
	MYB	MYOD1	NAB2	NCOA2	NF1	NFATC2
	NFIB	NR4A3	NRAS	NUTMI	NUTM2A	NUTM2B
	PALB2	PATZ1	PAX3	PAX7	PDGFB	PDGFRA
	PRKACA	PRKD1	RANBP2	ROS1	SDHA	SDHB
	SDHC	SDHD	SMARCB1	SS18	SSX1	SSX2
	SSX4	STAT6	SUZ12	TAF15	TCF12	TERT
	TFE3	TFEB	TFG	TP53	TPM3	TPM4
	TRAF7	TSPAN31	VGLL2	WT1	WWTR1	YAP1
	YWHAE	ZC3H7B

The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on the respective product pages.

Includes key guideline biomarkers, emerging biomarkers, and pan-cancer biomarkers. Content analysis provided by Velsera based on software Knowledgebase v8.5 (February 2023).
Genes with biomarkers of significance linked to current drug labels or guidelines.
Genes with biomarkers of potential significance based on presence in clinical trials.
CNS, central nervous system.

Product comparison

	TruSight Oncology 500	TruSight Oncology 500 High-Throughput	TruSight Oncology 500 ctDNA v2
Assay time	4–5 days from sample to results	4–5 days from sample to results	3-4 days from purified nucleic acid to variant report
Automation capability	Liquid handling robot(s)	Liquid handling robot(s)	Liquid handling robot(s)
Automation details	Explore available automation methods	Explore available automation methods	Explore available automation methods
Cancer type	Pan-cancer, Solid tumor	Pan-cancer, Solid tumor	Pan-cancer, Solid tumor
Content specifications	Targeted sequencing of DNA from 523 genes and RNA from 55 genes for a total of 1.94 Mb panel size. MSI and TMB measurement included. The optional TruSight Oncology 500 HRD kit (not available in Japan) content includes coverage of ~25K SNPs to assess homologous recombination deficiency through a comprehensive genomic instability score (LOH+TAI+LST) powered by Myriad Genetics.	Targeted sequencing of DNA from 523 genes of interest and RNA from 55 genes, for a total of 1.94 Mb panel size. MSI and TMB measurement included.	Targeted selection of 523 genes (full coding sequence) for a total of 1.94 Mb panel size. Immuno-oncology biomarker coverage: TMB and MSI Guideline coverage: Broad coverage of key guidelines for multiple solid tumor types Clinical trial coverage: Over 600 clinical trials (based on Velsera Knowledgebase, as of February 2023).
Description	Assay that enables comprehensive genomic profiling from FFPE tissue and runs on the NextSeq 550 System or NextSeq 550Dx Instrument (in Research Mode) and can batch up to eight samples at a time.	A high-throughput comprehensive NGS assay to identify key biomarkers in guidelines and >1K clinical trials from a streamlined workflow using the NextSeq 1000, NextSeq 2000, NovaSeq 6000, NovaSeq 6000Dx (in research mode) or the NovaSeq X Series. Includes coverage of immuno-oncology biomarkers TMB and MSI.	Provides a noninvasive research method for comprehensive genomic profiling of liquid biopsy samples (ctDNA from blood plasma). This liquid biopsy approach provides insights about intra- and inter-tumor heterogeneity using a minimally invasive sample collection approach to complement tissue-based CGP.
Hands-on time	~2.5 hr for automated workflow ~10.5 hr for manual workflow	~2.5 hr for automated workflow ~10.5 hr for manual workflow	~1.5 hr for automated workflow ~2.5 hr for manual workflow
Input quantity	40 ng DNA and/or 40 ng RNA	40 ng DNA and/or 40–80 ng RNA	20 ng cfDNA (4 ml of plasma)
Instruments	NextSeq 550 System, NextSeq 550Dx in research mode	NextSeq 2000 System, NextSeq 1000 System, NovaSeq X System, NovaSeq X Plus System, NovaSeq 6000Dx in research mode, NovaSeq 6000 System	NovaSeq X System, NovaSeq X Plus System, NovaSeq 6000 System, NovaSeq 6000Dx in research mode
Method	Target enrichment, Targeted DNA sequencing, Targeted RNA sequencing	Target enrichment, Targeted DNA sequencing, Targeted RNA sequencing	Target enrichment, Targeted DNA sequencing
Multiplexing	Up to 8-plex	NextSeq 1000 and 2000: P2 flow cell 8 samples, P3 flow cell 24 samples, P4 flow cell 36 samples. NovaSeq 6000/Dx: SP flow cell 16 samples, S1 flow cell 32 samples, S2 flow cell 72 samples, S4 flow cell 192 samples. NovaSeq X Series*: 1.5B cartridge 32 samples, 10B cartridge 192 samples, 25B 480 samples..	NovaSeq X Series: 4 samples on 1.5B flow cell, 24 samples on 10B flow cell NovaSeq 6000 System: 8 samples on S2 flow cell, 24 samples on S4 flow cell, 192 indexes maximum
Nucleic acid type	RNA, DNA	RNA, DNA	DNA
Sample throughput	8 samples/run	NextSeq 1000 and 2000: 8-36 samples/run, NovaSeq 6000/Dx: 16-192 samples/run, NovaSeq X: 32-480 samples/run, NovaSeq X Plus: 32-960 samples/run	4-48 samples/run
Specialized sample types	FFPE Tissue	FFPE Tissue	Circulating tumor DNA, Blood
Species category	Human	Human	Human
Technology	Sequencing	Sequencing	Sequencing
Variant class	Gene fusions, Transcript variants, Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs), Loss of heterozygosity (LOH), Somatic variants, Novel transcripts, Single nucleotide polymorphisms (SNPs), Structural variants	Gene fusions, Somatic variants, Novel transcripts, Structural variants, Transcript variants, Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs)	Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs)

FAQ

TruSight Oncology 500, TruSight Oncology 500 HT, and TruSight Oncology 500 ctDNA cover 523 cancer-related genes across DNA and RNA variants. (RNA variants are included with the TruSight Oncology 500 and TruSight Oncology 500 High-Throughput tissue-based assays only.) Genes were chosen based on alignment to guidelines, drug labels and clinical trials across multiple solid tumor types. For more details and the full gene list, see the TruSight Oncology 500 and TruSight Oncology 500 HT and TruSight Oncology 500 ctDNA data sheets.

HRD is a genomic signature related to a cell’s inability to repair double-stranded DNA breaks using the homologous recombination repair (HRR) pathway. When the HRR pathway is impaired, these breaks are either not repaired or repaired using an alternative pathway, leading to genomic instability and tumorigenesis.² TruSight Oncology 500 HRD is an add-on to TruSight Oncology 500 and assesses genomic instability (GIS) to help unlock tumor insights relevant for ovarian, breast, pancreatic, and prostate cancers.³

TruSight Oncology 500 ctDNA v2 includes similar content to TruSight Oncology 500 HT, but gene fusions are called from DNA only across 23 genes (compared to 55 for tissue). Additionally, HRD assessment is not included for TruSight Oncology 500 ctDNA v2.

/ Results

Resources

Research collaboration with National Center Japan

Read why researchers chose TruSight Oncology 500 ctDNA to study personalized cancer treatments for nasopharyngeal carcinoma.

TruSight Oncology 500 HRD at Oncopole Toulouse

Homologous recombination deficiency (HRD) is an important biomarker in ovarian cancer. Hear about TSO 500 HRD assay performance from Dr. Guillaume Bataillon at the Oncopole Toulouse laboratory in France.

NTRK fusion detection for identification of rare genomic events

Watch a webinar to learn about this rare but important biomarker and how CGP may enable use of emerging treatments such as NTRK inhibitors.

Speak to a specialist

Contact an Illumina representative to learn more about TruSight Oncology 500 products and find the right assay for your needs.

*HRD is available through an accessory kit to assess the Genomic Instability Score (GIS). HRD is only available with the addition of the TruSight Oncology 500 HRD kit to TruSight Oncology 500. Not available in Japan.
^†8 samples/run for TruSight Oncology 500 and 8–16 samples/run for TruSight Oncology 500 HRD; 16–192 samples/run for TruSight Oncology 500 High-Throughput.

References

Content analysis provided by Pierian Knowledgebase v8.5, February 2023.
O'Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547-560. doi:10.1016/j.molcel.2015.10.040
Yamamoto H, Hirasawa A. Homologous recombination deficiencies and hereditary tumors. Int J Mol Sci. 2021;23(1):348. doi:10.3390/ijms23010348

For every lab, everywhere

Illumina Single Cell 3' RNA Prep

NGS Workflow Finder

DRAGEN v4.3 now available on-premises and on-cloud

Illumina Proactive Instrument Performance Service

NovaSeq 6000 Reagent Kits v1.5

Bringing Greater Insights, Answers, and Breakthroughs to Light

Bringing Greater Insights, Answers, and Breakthroughs to Light

Bringing Greater Insights, Answers, and Breakthroughs to Light

Bringing Greater Insights, Answers, and Breakthroughs to Light

Bringing Greater Insights, Answers, and Breakthroughs to Light

Bringing Greater Insights, Answers, and Breakthroughs to Light

Bringing Greater Insights, Answers, and Breakthroughs to Light

Celebrate DNA Day with Your Students

Celebrate DNA Day with Your Students

Celebrate DNA Day with Your Students

Celebrate DNA Day with Your Students

Celebrate DNA Day with Your Students

Celebrate DNA Day with Your Students

Celebrate DNA Day with Your Students

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

TruSight Oncology 500 clinical research solutions

Three assays to fuel precision oncology research

TruSight Oncology 500 products

Key features and benefits

Comprehensive

Flexibility

Reliability

In-house

Timely

Scalable

Key biomarkers

Product comparison

FAQ

Which genes are covered by TruSight Oncology 500 products and how are they selected?

What is homologous recombination deficiency (HRD) assessment?

How is TruSight Oncology 500 ctDNA v2 different from TruSight Oncology 500 HT?

Resources